- Yahoo Finance
At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
Biogen Inc. Analyst Report: Biogen Inc. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan.
As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp.
At Biogen we are connected by a greater purpose to help improve the lives of patients, work fearlessly, and grow together. Hear from the best and brightest at Biogen on what inspires them every day and why you should join our team.
Biogen Idec Showcases Global, Multiple Sclerosis Leadership with More Than 45 Data Presentations at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. October 4, 2010. News Release.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment ...
The FDA approved Biogen's Alzheimer's disease drug aducanumab. It's the first drug cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer's and the first new medicine...
Redirecting to http://newsroom.biogen.com/news/news-releases.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY ...